Prof. PeptideProf. Peptide

Sermorelin

Growth HormoneResearch-Grade

Marketed as: Geref (discontinued)

Last reviewed: September 20, 2026

Quick Facts

What it is
A lab-made copy of the body's own GHRH signal — the 29-amino-acid fragment that prompts the pituitary to release its own growth hormone, studied for recovery, lean mass, and sleep.
How it's taken
Subcutaneous injection, once daily at bedtime
Half-life
~10–20 minutes
Typical research dose
Community-reported (unverified): 200–500 mcg once daily at bedtime. Cited adult trials used higher doses (700–2,000 mcg-equivalent) — see Dosing section
Research status
Formerly FDA-approved as Geref (discontinued 2008) — now research use only.
On this page
  1. 1.Where to source Sermorelin
  2. 2.What is Sermorelin?
  3. 3.How does Sermorelin work?
  4. 4.What is Sermorelin used for?
  5. 5.How long does Sermorelin take to work?
  6. 6.How is Sermorelin dosed?
  7. 7.How is Sermorelin administered?
  8. 8.What does Sermorelin stack well with?
  9. 9.What are the side effects of Sermorelin?
  10. 10.Does Sermorelin interact with other drugs?
  11. 11.How should Sermorelin be stored?
  12. 12.What are the limitations of Sermorelin research?
  13. 13.Sermorelin FAQ
  14. 14.References
  15. 15.Published Studies

Where to source Sermorelin

Sermorelin's brand product (Geref) was discontinued in 2008 (not for safety/efficacy reasons). It is currently available through licensed US compounding pharmacies with a prescription, or as research-grade peptide. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Capstone Peptides50% off
Professor's Pick

Accumark Labs · digital COAs

Shop Capstone Peptides
Amino Club40% off

ILS Laboratories · batch COAs

Shop Amino Club
Peptide Partners10% off
Professor's Pick

Kovera, Chromate and BioRegen · certificates checked at each lab

Shop Peptide Partners
Glacier Aminos10% off

Batch-traceable COAs · cold-chain shipping

Shop Glacier Aminos
Compare prices across 43 vendors

Also stocking Sermorelin

Modern Aminos, Mytide Lab, Oasis Labs, Peptide Basix — each carries a current price row for this compound.

Compare all 43 vendors stocking Sermorelin

See all 88 verified vendors · Compare every vendor's Sermorelin price

What is Sermorelin?

Sermorelin is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) — specifically the first 29 amino acids of native GHRH, which contain the entire biological activity of the parent hormone. Also known by the shorthand GRF (1-29) or GHRH(1-29)-NH2, it was originally developed by Serono and FDA-approved as Geref in 1990 for diagnosis of growth hormone deficiency in children. The brand was discontinued in 2008 (not for safety or efficacy reasons), but sermorelin remains widely used in compounding pharmacy and research-grade contexts. It stimulates pulsatile GH release through GHRH receptor activation, with a short half-life commonly reported at roughly 10–20 minutes, though no published pharmacokinetic study or label has been identified establishing this figure for Sermorelin, requiring frequent dosing. Often paired with ipamorelin for dual-pathway GH amplification, conceptually similar to the GH Stack (which uses CJC-1295 in place of sermorelin). New to peptide research? Start with the basics

Reported benefits:

  • Stimulates natural pulsatile growth hormone release via GHRH receptor
  • Increases IGF-1 through GH-mediated pathway
  • Supports lean muscle growth, fat reduction, recovery (downstream of GH)
  • Improved sleep quality reported with bedtime dosing
  • Bone density support in clinical research
  • Generally cleaner safety profile than other GHRH analogs (was FDA-approved)

Common research dose: Community-reported (unverified) protocols use 200–500 mcg subcutaneously once daily, typically at bedtime, over 3–6 month cycles. The cited adult human trials used higher per-dose amounts (roughly 700–2,000 mcg-equivalent) over shorter 6–16 week durations — see the Dosing section for the literature-vs-community comparison.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

How does Sermorelin work?

Sermorelin activates the GHRH receptor on pituitary somatotrophs with the same affinity and downstream signaling as endogenous GHRH — it IS the natural GHRH(1-29) sequence with no amino acid substitutions. The receptor is a Gαq-coupled GPCR triggering cAMP/PKA signaling. The short ~10–20 minute half-life produces sharp, physiologic GH pulses rather than continuous elevation, which is one reason sermorelin retains a cleaner safety profile than direct GH administration. Hypothalamic-pituitary feedback loops remain intact.

  1. GHRH Receptor Activation [1]. Sermorelin activates the GHRH receptor (GHRH-R) on pituitary somatotroph cells with the same affinity and downstream signaling as endogenous GHRH. The receptor is a Gαq-coupled GPCR that triggers cAMP/PKA signaling, driving GH synthesis and release.
  2. Pulsatile GH Release [2]. Sermorelin amplifies the natural pulsatile GH secretion pattern. Because the peptide is rapidly cleared (~10–20 minute half-life), it produces sharp, physiologic GH pulses rather than continuous elevation.
  3. Native GHRH Sequence [1]. Unlike CJC-1295 (which has 4 amino acid substitutions for DPP-IV resistance), sermorelin is the natural GHRH(1-29) sequence. This gives it a clean physiological profile but also makes it more rapidly degraded — the trade-off of using a more 'natural' peptide.
  4. IGF-1 Elevation [3]. Sustained sermorelin therapy raises IGF-1 levels through GH-mediated hepatic IGF-1 production. IGF-1 mediates many of the downstream anabolic and lipolytic effects.
  5. Hypothalamic Feedback Preserved. Because sermorelin works upstream of the pituitary (rather than directly replacing GH), the natural feedback loops involving somatostatin and IGF-1 remain intact. This is mechanistically safer than direct GH administration.

What is Sermorelin used for?

Sermorelin's research evidence base spans pediatric GH deficiency (original FDA-approval indication as Geref), adult GHRH replacement, cognitive effects in older adults, body composition, and sleep quality. Sermorelin has the longest FDA safety record of any GHRH analog discussed in research peptide contexts — most controlled human data predates the Geref discontinuation in 2008.

  1. Pediatric Growth Hormone Deficiency [2][5]. Original FDA approval indication. Geref (sermorelin) was used for both diagnosis and treatment of GH deficiency in children with idiopathic short stature. Chen et al. 1993 randomized 60 children with hypothalamic GH deficiency to GHRH(1-29)-NH2 (sermorelin, 30 or 60 mcg/kg/day) or GH for 6 months; growth was significantly better in the GH group, and the two sermorelin-dose groups did not differ from each other — a human RCT of sermorelin itself, though one whose own result favored GH over sermorelin for growth velocity.
  2. Adult GHRH Replacement [4]. Vittone et al. 1997 gave nightly self-administered GHRH (2mg SC) to 11 healthy men aged 64-76 for 6 weeks in an open-label, uncontrolled study with no placebo arm and no randomization. The paper reports no change in weight, BMI, waist-to-hip ratio, DEXA-measured muscle or fat, glucose, insulin, or lipids; two of six strength measures and one endurance measure improved. It does not support a body-composition or lipid-profile improvement claim.
  3. Cognitive Effects in Older Adults [4]. Baker et al. (2012) studied a related GHRH analog in older adults with mild cognitive impairment, with improvements in cognitive function reported.
  4. Body Composition. Sermorelin therapy in adults produces gradual increases in lean muscle mass and decreases in body fat over 4–6 month protocols. Effects are modest compared to direct HGH but with cleaner safety profile.
  5. Sleep Quality. Most subjective effects of sermorelin therapy involve improved sleep quality and recovery, likely tied to alignment of dosing with natural GH circadian peaks.

How long does Sermorelin take to work?

Sermorelin effects develop slowly. Khorram et al. 1997 [3] (a related GHRH analog, not identical to sermorelin) found IGF-1 and IGFBP-3 rose within 2 weeks of nightly dosing, and by the trial's 16-week endpoint, lean body mass had increased in men but not in women, with no other body-composition change in either sex. Sleep quality improvements are sometimes community-reported within 2–4 weeks, though no trial or label has been identified establishing that timeframe. Sermorelin's effects are generally more gradual than CJC-1295 due to the shorter half-life and lower per-dose potency.

IGF-1 and IGFBP-3 elevation appeared within 2 weeks of nightly dosing in Khorram et al. 1997 [3] (a related GHRH analog, not identical to sermorelin). By that trial's 16-week endpoint, lean body mass had increased in men but not in women, with no other body-composition change in either sex — this is the only sourced timeframe found for a body-composition effect; it is sex-specific and from a different (though closely related) compound. Sleep quality improvements are sometimes community-reported within 2–4 weeks, not established in a controlled study. Sermorelin's effects are generally more gradual than CJC-1295 due to the shorter half-life and lower per-dose potency — users who prefer convenience often switch to CJC-1295; users who prefer the most natural/gentle option stay with sermorelin.

How is Sermorelin dosed?

Three cited human studies report the actual doses used, at three different evidence levels, and none used the flat 200–1000 mcg adult figures that circulate in research communities. Sermorelin is administered as a subcutaneous injection; the short 10–20 minute half-life means effects depend entirely on dose timing.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

  1. Pediatric GH deficiency, Chen et al. 1993 [5]. Human RCT (n=60, children with hypothalamic GH deficiency, randomized to GH or GHRH(1-29)-NH2 for 6 months). The sermorelin arms used 30 or 60 mcg/kg/day — the 30 mcg/kg/day figure is also the dose the FDA-approved Geref label used for this indication. The trial itself found growth was significantly better with GH than with either sermorelin dose.
  2. Age-advanced adults, Khorram et al. 1997 [3]. Human RCT (single-blind, randomized, placebo-controlled, n=19, ages 55–71). Used a related GHRH analog, [Nle27]GHRH(1-29)-NH2 — one amino acid substituted from native sermorelin — at 10 mcg/kg SC nightly for 16 weeks (after 4 weeks of placebo). For a 70 kg adult that is roughly 700 mcg/night, within the range community protocols use, though the compound tested was not identical to sermorelin.
  3. Elderly men, Vittone et al. 1997 [4]. Human Observational (open-label, uncontrolled, no placebo, n=11, ages 64–76). Used native GHRH(1-29) at a flat 2,000 mcg (2 mg) SC nightly for 6 weeks — roughly 4–10× the community-reported adult dose below. The paper reported no change in weight, BMI, waist-to-hip ratio, or DEXA body composition at this dose.

Community-reported practice (unverified)

  1. Commonly circulated adult dose. 200–500 mcg subcutaneously once daily at bedtime — lower than every cited adult dose above (700–2,000 mcg-equivalent) and not itself drawn from a trial.
  2. Higher dose (unverified). Up to 1,000 mcg per dose for patients with more severe GHRH-axis decline — closer to, but still below, the Khorram et al. per-kg figure for an average adult.
  3. Empty stomach (unverified). Insulin spikes from food are reported to blunt GH release — wait 2+ hours after eating, 30 min before next meal; not a figure from the cited trials, which do not report food timing.
  4. Cycle length (unverified). 3–6 months is common for adult GHRH-replacement protocols — longer than Khorram (16 weeks) or Vittone (6 weeks); some patients use continuously under clinical supervision.
  5. Sermorelin + GHRP stack (unverified). Some protocols pair sermorelin with ipamorelin to amplify GH release via dual-pathway activation; not tested in any cited trial.

Sermorelin produces gentler, more physiological effects than CJC-1295 with DAC because of the shorter half-life. Most users describe sermorelin as feeling “cleaner” than direct HGH or longer-acting analogs. The trade-off is slower onset and need for daily dosing — patients who prefer convenience often choose CJC-1295 instead.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule. The Sermorelin reconstitution calculator works the same arithmetic against the vial sizes tracked for this compound.

How is Sermorelin administered?

Sermorelin is given as a subcutaneous injection — under the skin, not into muscle — once daily at bedtime using a small insulin syringe. The short half-life makes bedtime alignment with natural overnight GH peaks essential. Empty-stomach dosing is required for full GH response. For the practical mechanics of insulin syringes, units vs mcg conversion, and subcutaneous technique, see the syringes and injection technique guide.

  1. Route. Subcutaneous injection. Common sites: abdomen, thigh, upper arm.
  2. Time of day. Bedtime is strongly preferred. Reported protocols inject 30–60 minutes before sleep, aligning with the natural overnight GH peak.
  3. With or without food. An empty stomach is the convention, waiting 2+ hours after eating and 30 min before the next meal.
  4. Site rotation. Rotating sites each injection, with at least an inch between consecutive sites, is the convention for limiting localized irritation.
  5. Missed dose. Reported practice skips and resumes at the next scheduled dose — short half-life makes catch-up unnecessary.
  6. Cycle structure. 3–6 months common; continuous use under clinical supervision also documented.

Timing context. Sermorelin's ~10–20 minute half-life makes timing critical. The body's largest natural GH release happens in the first 90 minutes of deep sleep — bedtime dosing (30–60 min before sleep) stacks the sermorelin pulse onto this natural peak. Empty-stomach timing matters because insulin from food blunts the GH response.

AspectReported
FrequencyOnce daily in every cited trial [3][4][5] and in community-reported (unverified) practice; a 3–6 month cycle is community-reported, longer than the 6–16 week durations used in the cited trials.
Best time of dayThe most reproducible endogenous GH pulse occurs shortly after sleep onset, coinciding with slow-wave sleep — established sleep endocrinology (Van Cauter & Plat, 1996, J Clin Endocrinol Metab); bedtime dosing on that reasoning is a commonly reported research convention, not itself trial-tested.
FoodEmpty stomach required — 2+ hours after eating, 30+ min before next meal
Injection site rotationRotating between the abdomen, thigh, and upper arm without reusing the same site for the next injection is standard subcutaneous-injection practice — documented in FDA-approved injectable labels generally (e.g., Wegovy's and Mounjaro's own instructions to rotate with each dose), not specific to Sermorelin.
Half-life~10–20 minutes
Steady-statePer-pulse effect rather than traditional steady-state — each dose triggers a discrete GH pulse

Reconstitution math. Water volume sets concentration: a lower volume yields a higher concentration and a smaller syringe draw for a given mg amount, and the reverse for a higher volume. Sermorelin research vials are typically 5 mg. Because doses are 200–500 mcg (sometimes up to 1 mg), 2 mL reconstitution is the common research convention — it gives clean whole-number units across the typical dose range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL). The table assumes a 5 mg vial.

BAC waterConcentration100 mcg dose250 mcg dose500 mcg dose1 mg dose
1 mL5 mg/mL2 units5 units10 units20 units
2 mL2.5 mg/mL4 units10 units20 units40 units
3 mL1.67 mg/mL6 units15 units30 units60 units

Units vs mcg. At a 5 mg vial, each unit drawn delivers 50 mcg of Sermorelin at 1 mL reconstitution, 25 mcg at 2 mL, and 16.7 mcg at 3 mL — the reconstitution volume determines the mcg-per-unit conversion. For a primer on reading insulin syringes and choosing the right barrel size, see our guide on syringes and injection technique.

What does Sermorelin stack well with?

Sermorelin's canonical pairing is ipamorelin — the dual-pathway combination (GHRH receptor + ghrelin receptor) produces synergistic GH release. Recovery peptides (BPC-157, TB-500) pair cleanly for systemic recovery. IGF-1 LR3 stacks for direct receptor activation alongside endogenous GH stimulation. CJC-1295 acts on the same GHRH receptor — a redundant mechanism.

  1. Ipamorelin. The most popular pairing. Ipamorelin (ghrelin receptor) + sermorelin (GHRH receptor) produces synergistic GH release through dual-pathway activation — conceptually equivalent to the GH Stack (which uses CJC-1295 instead of sermorelin).
  2. BPC-157 / TB-500. Wolverine Stack paired for recovery support during anabolic protocols.
  3. IGF-1 LR3. IGF-1 LR3 combined for direct IGF-1 receptor activation alongside endogenous GH stimulation.
  4. Conflicts: CJC-1295 or other GHRH analogs. CJC-1295 targets the same GHRH receptor — combining is redundant. Choose one based on dosing convenience and feel.
  5. Resistance training. Exercise-induced GH release amplified when paired with sermorelin.

What are the side effects of Sermorelin?

Sermorelin had over 18 years of FDA-approved clinical use as Geref before the brand was discontinued (for commercial reasons, not safety or efficacy). The most-reported user effects are mild injection-site reactions, transient facial flushing, and mild headache especially with first doses.

Common (most users)

  1. Injection site reactions. Mild redness or irritation, typically resolves within hours.
  2. Mild facial flushing or warmth. Transient (vasodilation); resolves within ~30 minutes.
  3. Headache. Especially first doses; typically mild.

Less common (moderate)

  1. Mild fluid retention. Consistent with GH/IGF-1 elevation.
  2. Joint pain or stiffness. Common during anabolic phases of GH-axis cycling.
  3. Mild numbness or tingling. Uncommon; related to fluid retention.

Serious (rare)

  1. Allergic reactions. Uncommon — was FDA-approved with established safety profile.
  2. Theoretical tumor-growth risk. GH/IGF-1 elevation could accelerate pre-existing tumors, so active malignancy is treated as a theoretical exclusion in research contexts.
  3. Hypothyroidism. Rare; monitored in long-term protocols.

Sermorelin had over 18 years of FDA-approved clinical use as Geref before the brand was discontinued (for commercial reasons, not safety or efficacy). The discontinuation of Geref was confirmed by the FDA as not being for safety or effectiveness reasons.

Does Sermorelin interact with other drugs?

Sermorelin's most important interactions are with anything that blunts GH release (insulin, corticosteroids) and with other GHRH analogs (redundant mechanism). Thyroid hormones may be affected in long-term use — monitor in protocols beyond 6 months. No major drug-drug pharmacokinetic interactions have been reported.

  1. Insulin and corticosteroids. Both blunt GH release; time injections away from meals and steroid administration.
  2. Other GHRH analogs (CJC-1295). Redundant mechanism, do not combine. Choose one GHRH analog.
  3. Direct HGH. Combining is generally unnecessary — sermorelin stimulates endogenous GH; adding exogenous GH is duplicative.
  4. Thyroid hormones. Sermorelin may affect thyroid function in long-term use; monitor in protocols beyond 6 months.

How should Sermorelin be stored?

  1. Lyophilized (powder) form: Store at -20°C for long-term storage; refrigerate at 2–8°C for short-term.
  2. Reconstituted solution: 2–8°C, refrigerated, is standard practice once dissolved. Prof. Peptide has not identified a manufacturer label, published study, or lab document establishing how long reconstituted research-grade Sermorelin remains stable — this page does not state a duration as fact.
  3. Reconstitution uses bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. The reconstituted solution is never frozen.
  5. Sermorelin is stored protected from light, in the original carton.
  6. A solution that is cloudy, discolored, or contains particles is discarded.

What are the limitations of Sermorelin research?

Sermorelin was FDA-approved as Geref — in 1990 as a diagnostic for growth-hormone secretion, and in 1997 for idiopathic GH deficiency in children — and discontinued in 2008. A 2013 FDA determination states it was not withdrawn for reasons of safety or effectiveness. Sermorelin remains accessible through licensed US compounding pharmacies with a prescription, and as research-grade peptide. Most published clinical evidence is from older studies; anti-aging and longevity uses are off-label. WADA prohibits sermorelin in sport under Section S2.

Sermorelin was FDA-approved as Geref — in 1990 as a diagnostic for growth-hormone secretion, and in 1997 for idiopathic GH deficiency in children — and discontinued in 2008. A 2013 FDA determination (Federal Register, March 4, 2013) states it was not withdrawn for reasons of safety or effectiveness. Sermorelin remains accessible through licensed compounding pharmacies in the US (with prescription) and as a research-grade peptide.

Most published clinical evidence is from older studies (1990s–2000s) using sermorelin in pediatric and adult GH deficiency contexts. Anti-aging and longevity uses are off-label and not formally validated through controlled trials.

The World Anti-Doping Agency prohibits sermorelin in sport under Section S2 (peptide hormones). Research-grade material sold outside compounding pharmacy channels is intended for laboratory use only and is not approved for human consumption.

Sermorelin FAQ

Is sermorelin FDA-approved?

Sermorelin was FDA-approved as Geref: a 0.05 mg ampule in 1990 as a diagnostic for growth-hormone secretion, and 0.5 mg and 1.0 mg vials in 1997 for idiopathic GH deficiency in children. Both were discontinued in 2008, and a 2013 FDA determination states they were not withdrawn for reasons of safety or effectiveness. Sermorelin is currently available through licensed compounding pharmacies (with prescription) or as research-grade peptide.

What's the difference between sermorelin and CJC-1295?

Sermorelin is the natural GHRH(1-29) fragment. CJC-1295 (without DAC) is the same fragment with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-IV degradation. This makes CJC-1295 more stable and longer-lasting. Sermorelin produces gentler, more physiological pulses; CJC-1295 produces stronger, longer effects. See the CJC-1295 vs Sermorelin vs Ipamorelin comparison for a side-by-side breakdown.

Should I use sermorelin or CJC-1295?

Sermorelin is the most natural/gentle option with the longest FDA safety record. CJC-1295 (without DAC) produces a slightly stronger and more durable effect. CJC-1295 with DAC allows weekly rather than daily dosing. All three work through the same receptor — the difference is mostly pharmacokinetics.

How long until I see results from sermorelin?

In Khorram et al. 1997 (a related GHRH analog, not identical to sermorelin), IGF-1 and IGFBP-3 rose within 2 weeks of nightly dosing, and lean body mass increased by the trial's 16-week endpoint in men but not in women, with no other body-composition change in either sex. Sleep improvements are sometimes community-reported within 2–4 weeks, not established in a controlled study. Sermorelin's effects are generally slower than CJC-1295 because of the shorter half-life and gentler per-dose effect.

Why bedtime dosing?

The body releases the majority of its daily GH during the first 90 minutes of deep sleep. Sermorelin's short half-life means bedtime injection captures and amplifies this natural peak. Dosing earlier in the day still works but produces smaller effects.

Can sermorelin be used long-term?

Sermorelin has a longer track record of long-term human use than other GHRH analogs because of its decades of FDA-approved clinical use. Many adult anti-aging protocols use it for 6–12 months continuously under medical supervision. Monitoring for IGF-1 elevation, glucose tolerance, and thyroid function is recommended for sustained use.

Is sermorelin safer than direct HGH?

Yes, mechanistically. Sermorelin works upstream of the pituitary, preserving the body's natural feedback loops. The GH it releases is endogenous and pulsatile, matching natural physiology. Direct HGH bypasses these regulatory mechanisms and can cause supraphysiologic GH levels that lead to side effects like edema, joint pain, and insulin resistance more readily than sermorelin.

Where can I buy sermorelin?

Through licensed US compounding pharmacies with a prescription, or through specialty research peptide vendors as research-grade material. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. https://pubmed.ncbi.nlm.nih.gov/18031173/
  3. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in older men and women. J Clin Endocrinol Metab. 1997;82(5):1472-9. https://pubmed.ncbi.nlm.nih.gov/9141536/
  4. Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/
  5. Chen RG, Shen YN, Yei J, et al. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr Suppl. 1993;388:32-5; discussion 36. https://pubmed.ncbi.nlm.nih.gov/8329830/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Clinical Interventions in Aging / PMC · 2006Open Access
Sermorelin: A Better Approach to Management of Adult-Onset Growth Hormone Insufficiency? →

Walker RF

The most widely cited review arguing for sermorelin as a safer alternative to direct growth hormone replacement therapy (GHRT). The paper explains a key advantage of sermorelin over exogenous GH: because sermorelin stimulates the pituitary to produce its own GH rather than administering GH directly, the natural negative feedback mechanisms (somatostatin regulation) remain intact — making overdose essentially impossible. Walker argues this represents a more physiologically appropriate approach than rhGH.

Journal of Clinical Endocrinology & Metabolism · 1992Paywalled
Growth Hormone (GH)-Releasing Hormone-(1-29) Twice Daily Reverses the Decreased GH and Insulin-Like Growth Factor-I Levels in Old Men →

Corpas E, Harman SM, Pineyro MA, et al.

One of the foundational human studies of sermorelin in elderly men ages 60–78. High-dose sermorelin elevated mean 24-hour GH levels, peak GH amplitude, and GH area under the curve. Strikingly, elderly men who had lower baseline IGF-1 levels than young controls saw IGF-1 rise toward youthful levels with sermorelin treatment — and these elevations persisted above baseline for two weeks after stopping treatment, suggesting lasting pituitary sensitization.

PMC / JAMA Neurology · 2013Open Access
Growth Hormone-Releasing Hormone Effects on Brain GABA Levels in Mild Cognitive Impairment and Healthy Aging →

Friedman SD, Baker LD, Borson S, et al.

A randomized clinical trial examining GHRH's effects on brain neurochemistry and cognitive function in healthy older adults and adults with mild cognitive impairment (MCI). Participants self-administered daily tesamorelin (a GHRH analog equivalent to sermorelin for this purpose) for 20 weeks. The study found changes in brain GABA levels and cognitive performance improvements.

PMC / Translational Andrology and Urology · 2020Open Access
Beyond the Androgen Receptor — Growth Hormone Secretagogues in the Management of Hypogonadal Males →

Sinha DK, Balasubramanian A, Tatem AJ, et al.

A clinical review covering sermorelin's role in treating hypogonadal males with metabolic syndrome. The paper documents a unique finding from sermorelin research: unlike other GH secretagogues which work via the ghrelin pathway, sermorelin uniquely stimulates FSH and LH release — implying a potential role in supporting endogenous testosterone production alongside GH stimulation.

Growth HormoneGHRH AnalogAnti-AgingResearch-Grade

Related Peptides

CJC-1295IpamorelinTesamorelinMK-677IGF-1 LR3

Related Blends

Sermorelin + IpamorelinGH StackWolverine Stack

Comparisons

CJC-1295 vs Sermorelin vs Ipamorelin

We may earn commissions from peptide vendor affiliate links.

Have a question about Sermorelin? Send us an email